Xtx Topco LTD Cerus Corp Transaction History

Xtx Topco LTD

$1.72 Billion
Q3 2025

A detailed history of Xtx Topco LTD transactions in Cerus Corp stock. As of the latest transaction made, Xtx Topco LTD holds 287,400 shares of CERS stock, worth $465,588. This represents 0.03% of its overall portfolio holdings.

Number of Shares

287,400

Previous 117,756 144.06%

Holding current value

$465,588

Previous $166,000 174.7%

% of portfolio

0.03%

Previous 0.01%

13 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2025 Nov 14, 2025	BUY	$1.16 - $1.6 $196,787 - $271,430	169,644 Added 144.06%	287,400 $456,000
Q2 2025 Aug 12, 2025	SELL	$1.22 - $1.51 $91,518 - $113,272	-75,015 Reduced 38.91%	117,756 $166,000
Q1 2025 May 07, 2025	SELL	$1.39 - $2.15 $97,832 - $151,323	-70,383 Reduced 26.75%	192,771 $267,000
Q4 2024 Feb 13, 2025	BUY	$1.52 - $2.03 $128,778 - $171,987	84,723 Added 47.48%	263,154 $405,000
Q3 2024 Nov 14, 2024	BUY	$1.7 - $2.39 $47,707 - $67,070	28,063 Added 18.66%	178,431 $310,000

Q2 2024 Aug 12, 2024	BUY	$1.62 - $2.04 $243,596 - $306,750	150,368 New	150,368 $264,000
Q4 2023 Feb 13, 2024	BUY	$1.25 - $2.35 $58,388 - $109,770	46,711 New	46,711 $100,000
Q2 2023 Aug 14, 2023	SELL	$1.79 - $2.9 $93,774 - $151,925	-52,388 Reduced 34.2%	100,776 $247,000
Q1 2023 May 12, 2023	BUY	$2.65 - $3.81 $24,973 - $35,905	9,424 Added 6.56%	153,164 $454,000
Q4 2022 Feb 14, 2023	BUY	$3.38 - $4.22 $178,362 - $222,689	52,770 Added 58.01%	143,740 $524,000
Q3 2022 Nov 14, 2022	BUY	$3.43 - $5.83 $312,027 - $530,355	90,970 New	90,970 $327,000
Q2 2022 Aug 15, 2022	SELL	$4.41 - $5.69 $78,912 - $101,816	-17,894 Closed	0 $0
Q1 2022 May 13, 2022	BUY	$4.81 - $6.99 $86,070 - $125,079	17,894 New	17,894 $98,000

Others Institutions Holding CERS

# of Institutions

166

Shares Held

135M

Call Options Held

126K

Put Options Held

30.1K

View Full List

About CERUS CORP

Ticker CERS
Exchange NASDAQ
Sector Healthcare
Industry Medical Devices
Shares Outstandng 177,090,000
Market Cap $287M
Description
Cerus Corporation operates as a biomedical products company. The company focuses on developing and commercializing the INTERCEPT Blood System to enhance blood safety. Its INTERCEPT Blood System, a proprietary technology for controlling biological replication that is designed to reduce blood-borne pathogens in donated blood components intended fo...

More about CERS

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Xtx Topco LTD, based on Form 13F filings with the SEC.

News

Stay updated on Xtx Topco LTD with notifications on news.

Account